Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
4 clinical trials · Condition
◉ Watch Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (NCT03468218) | Emory University | 2018-09-18 |
| Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT02567422) | National Cancer Institute (NCI) | 2017-04-17 |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (NCT01810913) | National Cancer Institute (NCI) | 2013-03-22 |
| Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01064479) | M.D. Anderson Cancer Center | 2010-02-05 |
Track Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 automatically
Every clearance here is in the API, with alerts when new ones post.